粪肠球菌临床分离株中ParC和GyrA蛋白改变与对九种不同氟喹诺酮类药物耐药性的关联
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.
作者信息
Brisse S, Fluit A C, Wagner U, Heisig P, Milatovic D, Verhoef J, Scheuring S, Köhrer K, Schmitz F J
机构信息
Eijkman-Winkler Institute, Utrecht University, 3584 CX, Utrecht, The Netherlands.
出版信息
Antimicrob Agents Chemother. 1999 Oct;43(10):2513-6. doi: 10.1128/AAC.43.10.2513.
Abstract
The parC and gyrA genes of 73 ciprofloxacin-resistant and 6 ciprofloxacin-susceptible Enterococcus faecium clinical isolates were partly sequenced. Alterations in ParC and GyrA, possibly in combination with other resistance mechanisms, severely restricted the in vitro activities of the nine quinolones tested. For all isolates, clinafloxacin and sitafloxacin showed the best activities.
摘要
对73株耐环丙沙星和6株环丙沙星敏感的屎肠球菌临床分离株的parC和gyrA基因进行了部分测序。ParC和GyrA的改变，可能与其他耐药机制共同作用，严重限制了所测试的9种喹诺酮类药物的体外活性。对于所有分离株，克林沙星和司帕沙星显示出最佳活性。
相似文献
1
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.
Antimicrob Agents Chemother. 1999 Oct;43(10):2513-6. doi: 10.1128/AAC.43.10.2513.
2
Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.
Antimicrob Agents Chemother. 1999 Apr;43(4):947-9. doi: 10.1128/AAC.43.4.947.
3
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. doi: 10.1128/AAC.42.11.2810.
4
Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
Antimicrob Agents Chemother. 2001 Mar;45(3):734-8. doi: 10.1128/AAC.45.3.734-738.2001.
5
Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
Antimicrob Agents Chemother. 2001 Aug;45(8):2263-8. doi: 10.1128/AAC.45.8.2263-2268.2001.
6
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. doi: 10.1128/AAC.43.2.329.
7
Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
J Antimicrob Chemother. 1997 Oct;40(4):543-9. doi: 10.1093/jac/40.4.543.
8
Development of fluoroquinolone resistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae isolates in Japan.
J Urol. 1998 Jun;159(6):2215-9. doi: 10.1016/S0022-5347(01)63308-1.
9
Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.
Antimicrob Agents Chemother. 1996 Apr;40(4):1020-3. doi: 10.1128/AAC.40.4.1020.
10
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.
Antimicrob Agents Chemother. 1998 Feb;42(2):433-5. doi: 10.1128/AAC.42.2.433.
引用本文的文献
1
Virulence gene detection and antimicrobial resistance analysis of Enterococcus faecium in captive giant pandas (Ailuropoda melanoleuca) in China.
Acta Vet Scand. 2023 Feb 3;65(1):4. doi: 10.1186/s13028-023-00668-z.
2
Identification and characterization of resistance and pathogenicity of . in samples of donor breast milk.
World J Clin Pediatr. 2020 Nov 19;9(3):53-62. doi: 10.5409/wjcp.v9.i3.53.
3
Association of mutation patterns in GyrA and ParC genes with quinolone resistance levels in lactic acid bacteria.
J Antibiot (Tokyo). 2015 Feb;68(2):81-7. doi: 10.1038/ja.2014.113. Epub 2014 Sep 10.
4
Antibiotic resistances of starter and probiotic strains of lactic acid bacteria.
Appl Environ Microbiol. 2007 Feb;73(3):730-9. doi: 10.1128/AEM.02105-06. Epub 2006 Nov 22.
5
High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium.
J Clin Microbiol. 2006 Mar;44(3):1059-64. doi: 10.1128/JCM.44.3.1059-1064.2006.
6
Automated ribotyping of vancomycin-resistant Enterococcus faecium isolates.
J Clin Microbiol. 2002 Jun;40(6):1977-84. doi: 10.1128/JCM.40.6.1977-1984.2002.
7
Gatifloxacin: a review of its use in the management of bacterial infections.
Drugs. 2002;62(1):169-207. doi: 10.2165/00003495-200262010-00007.
本文引用的文献
1
Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?
J Antimicrob Chemother. 1998 Dec;42(6):683-8. doi: 10.1093/jac/42.6.683.
2
Primary targets of fluoroquinolones in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1999 Feb;43(2):410-2. doi: 10.1128/AAC.43.2.410.
3
Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1999 Jan;43(1):187-9. doi: 10.1128/AAC.43.1.187.
4
The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals.
J Antimicrob Chemother. 1998 Oct;42(4):489-95. doi: 10.1093/jac/42.4.489.
5
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. doi: 10.1128/AAC.42.11.2810.
6
The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
J Antimicrob Chemother. 1998 Aug;42(2):179-87. doi: 10.1093/jac/42.2.179.
7
Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.
Antimicrob Agents Chemother. 1998 Sep;42(9):2304-11. doi: 10.1128/AAC.42.9.2304.
8
Current susceptibilities of staphylococci to glycopeptides determined as part of an international resistance surveillance programme. Sentry Antimicrobial Surveillance Program.
J Antimicrob Chemother. 1998 Jul;42(1):119-21. doi: 10.1093/jac/42.1.119.
9
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Diagn Microbiol Infect Dis. 1998 Jun;31(2):343-7. doi: 10.1016/s0732-8893(98)00019-4.
10
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
Antimicrob Agents Chemother. 1998 May;42(5):1249-52. doi: 10.1128/AAC.42.5.1249.
Zotero 插件